Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of oral PHA-022121 in healthy adults
NL-OMON49075Active, not recruiting
- Sponsor
- Pharvaris
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in hereditary angioedema (HAE) comparing PHA-022121 multiple ascending dose with Placebo (2 arms). Primary endpoints: Safety and tolerability, PHA-022121 plasma pharmacokinetics on Day 1 and 4 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON49075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49075.